Chief Legal Officer
Rob has closed more than 50 strategic transactions across a broad range of research and development (R&D) collaborations, licensing agreements, and mergers and acquisitions. Before joining Affinia Therapeutics, Rob was a principal at the law firm Faber Daeufer & Itrato PC, co-leading its R&D collaborations and licensing practice, and working with prominent gene therapy clients. Prior to that, he was vice president and head of business strategy for GSK’s biotech partnering unit and assistant general counsel at GSK supporting worldwide business development and R&D operations. Earlier in his career, Rob held multiple roles including biotech patent attorney at Akin, Gump, Strauss, Hauer & Feld, and research biochemist in bioprocess R&D at Merck. Rob received a B.S. in biochemistry from Albright College, an M.S. in biochemistry from Rutgers University, and a J.D. from Temple University.